Cellectricon Partners With The Automation Partnership Bringing Next Generation Ion Channel Screening System to Market
Published: Dec 05, 2008
GOTHENBURG, Sweden, December 3 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced the signing of a collaborative agreement with The Automation Partnership (TAP) in the UK, manufacturers of advanced automated systems for cell culture, sample management and high throughput screening applications. Under the agreement TAP will co-develop and manufacture the Dynaflow(R)HT System, Cellectricon's next generation high throughput ion channel screening platform. Dynaflow(R)HT will be launched and commercially available in 2009.
Addressing the limitations of current ion channel screening technologies, the Dynaflow(R)HT yields an unmatched level of automated throughput while still delivering unique measurement data quality. The concept and technology has been developed and validated over the last three years by Cellectricon in partnership with AstraZeneca.
"We are excited to partner with TAP who are world-renowned for manufacturing industrial quality automation," says Jonas Ohlsson, CEO at Cellectricon. "To bring this fully automated state-of-the-art high throughput electrophysiology system to the market is a milestone for ion channel screening. The system offers unmatched throughput, cost per data point and reliability/predictability."
"The Automation Partnership (TAP) are very pleased to have the opportunity to work with Cellectricon in automating their unique high throughput microfluidic screening platform," says Andy Morffew Chief Executive Officer. "We are looking forward to supporting this system with a wide range of excellent technical and professional services, designed to ensure customers gain optimum return from their capital investment."
Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007, the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.
About The Automation Partnership
The Automation Partnership (TAP) is a world leader in the design, development and implementation of advanced automation systems for the life sciences research industry. TAP specializes in automation for cell culture, sample management and advanced screening applications. These range from multi-million pound large-scale drug discovery facilities to standalone bench-top products. TAP also offers custom engineering services to customers requiring unique solutions for complex and challenging research problems.
TAP's customers include the world's top pharmaceutical and biotechnology companies, key service providers and leading research institutions including: Amgen, AstraZeneca, ATCC, GlaxoSmithKline, Loughborough University, Max Planck Institute, Merck, Oxford University, Stem Cell Sciences, UK Biobank and Wyeth.
CONTACT: Contact Cellectricon: Jonas Ohlsson, CEO, Phone:
+46(0)709-73-47-92, E-mail: email@example.com; Susanne
Fagerlund, VP Marketing & Communications, Phone: +46(0)31-760-35-15, Email:
firstname.lastname@example.org; Contact The Automation Partnership:
Matthew Walker, Head of Communications, Phone: +44(0)1763-22-72-00, E-mail: